Please login to the form below

Not currently logged in
Email:
Password:

Qtern

This page shows the latest Qtern news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

Among the other highlights from the CHMP meeting was the withdrawal by AstraZeneca (AZ) of an application to market diabetes combination Qtern (saxagliptin/dapagliflozin).

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    AZ gets US approval for diabetes combo Qtern. Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015. ... The US FDA has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes, after rejecting the drug in 2015.

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    And two other new launches, Bevespi (glycopyrrolate and formoterol fumarate) for chronic obstructive pulmonary disease (COPD) and combination diabetes therapy Qtern (saxagliptin and dapagliflozin), will also help drive the recovery, said

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    EU clears AZ's FDA-rejected diabetes combination. Approval of two-drug therapy Qtern presents first-to-market advantage in Europe. ... The European Commission has approved AstraZeneca's Qtern, a two-drug therapy for type 2 diabetes that was turned down

  • Gilead, Merck get CHMP backing for new hep C combinations Gilead, Merck get CHMP backing for new hep C combinations

    At its meeting last week the CHMP also gave a green light to AstraZeneca's DPP-4 inhibitor/SGLT2 inhibitor combination Qtern (saxagliptin/dapagliflozin) as a treatment for type 2 diabetes.

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics